Management of tricuspid valve insufficiency. Replacement with Hancock bioprosthesis or suture annuloplasty.
Forty-seven patients who underwent tricuspid valve replacement (TVR) or tricuspid annuloplasty (TA) combined with aortic (AVR) or mitral valve replacement (MVR) at Henry Ford Hospital, from 1971 to 1977 are reviewed. Thirty-three patients underwent TVR with a Hancock valve combined with MVR or AVR; hospital mortality was 30% (10 to 33) and was higher at the beginning of the series when smaller valves were used. No valve dysfunction has been seen with mean follow-up time of 36.7 months, ranging from 4 to 60 months. Good functional improvement was accomplished in all patients. Fourteen patients underwent TA; hospital mortality was 21% (3 of 14) with one late mortality (9%); good functional improvement was accomplished in all patients. However, one patient presented 11 months following surgery with tricuspid insufficiency after a period of improvement. For patients with severely deformed valves a large size Hancock valve is recommended. For insufficiency alone tricuspid annuloplasty is recommended.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D006328:Cardiac Catheterization; D002648:Child; D005260:Female; D006350:Heart Valve Prosthesis / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D012214:Rheumatic Heart Disease / Q000150:complications; D013537:Sutures; D014262:Tricuspid Valve Insufficiency / Q000150:complications / Q000601:surgery*